Publications by authors named "M Scheffler"
Background: Visual rating scales are routinely used in clinical radiology to assess brain atrophy on scans of patients with suspected neurodegenerative conditions. Limbic predominant age-related TDP-43 encephalopathy (LATE) has recently been described, featuring early and severe atrophy of the amygdala. However, there is currently no scoring system specifically designed to assess amygdalar atrophy on MRI.
View Article and Find Full Text PDFObjectives: We investigated tau and neurodegeneration patterns and clinical phenotypes in carriers of a specific pathogenic variant in the PSEN1 gene and 1 nonaffected relative.
Methods: We included 3 symptomatic carriers of the c.436 A>C, p.
Article Synopsis
- This study evaluated the impact of SGLT2 inhibitors on heart-related health outcomes and mortality rates, focusing on different kidney disease risk groups (KDIGO and UACR).
- Researchers analyzed data from 14 large randomized trials involving over 97,000 participants and found that SGLT2 inhibitors significantly reduced major cardiovascular events and all-cause mortality, with particular benefits noted in high-risk kidney disease groups.
- The findings suggest that SGLT2 inhibitors can improve cardiovascular health, especially in patients with severe kidney disease.
Our recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC. While TXNRD1 RNA testing was the best-performing single-gene test, the combination of single-gene screening and validation with the K1N2-score achieved the highest performance when predicting mutation status or pathway activation.
View Article and Find Full Text PDF